U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Center for Drug Evaluation and Research (CDER)
  5. CDER Offices and Divisions
  6. Office of Cardiology, Hematology, Endocrinology and Nephrology - Division of Diabetes, Lipid Disorders, and Obesity (DDLO)
  1. CDER Offices and Divisions

Office of Cardiology, Hematology, Endocrinology and Nephrology - Division of Diabetes, Lipid Disorders, and Obesity (DDLO)

The Division of Diabetes, Lipid Disorders, and Obesity (DDLO) regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologics Licensing Applications (BLAs) for drugs and biologics intended for the prevention, treatment, or diagnosis of conditions including:

  • Type 1 and Type 2 diabetes mellitus
  • Weight loss and weight maintenance
  • Lipodystrophy

Contact Us

Mailing Address:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Diabetes, Lipid Disorders, and Obesity (DDLO)
5901-B Ammendale Road
Beltsville, MD 20705-1266
Phone: (301) 796-2290
Fax: (301) 595-2123

Resources 



Back to Top